1073TiP A phase I, first-in-human, multicenter, open-label, dose-escalation study of IPH5201 as monotherapy or in combination with durvalumab ± oleclumab in advanced solid tumours. - Powderly, J.; Bendell, J.C.; Carneiro, B.A.; Italiano, A.; Mercadé, T. Macarulla; Alvarez, E. Castanon; Imbimbo, M.; Massard, C.; Mueller, N.; Gascó -Hernandez, A. (Annals of Oncology, 2020)